KVUE

#414
Kenvue Inc.
17.3800 USD
+0.61%
Сектор: Основное потребление
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
17.3500
17.3950
Годовой диапазон
14.0200
19.1750
Дневное изменение
+0.61%
Месячное изменение
-1.25%
6-месячное изменение
+15.25%
Годовое изменение
+15.25%
Предыдущее закрытие
17.2750
Открыть
17.3700
Bid
Ask
Минимум
17.3500
High
17.3950
Объем
1 836
Открыть полный график

Financials

Обзор Отчетность Статистика Дивиденды
Квартал Год
  • Market Capitalization 33.3128 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
22.62
Коэффициент цена/денежный поток
2.19
Дивиденды на акцию
0.82
Дивидендная доходность, %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

Новости